K201 improves norepinephrine-induced diastolic dysfunction with preserved ejection fraction

Drug Development Research

Volumn 67, Issue 11, 2006, Pages 852-861

  Kaneko, Noboru ^a   Matsuda, Ryuko ^a   Ohtani, Naoyuki ^a   Nakajima, Takahide ^a   Arikawa, Takuo ^a   Suzuki, Hidehiko ^a   Toyoda, Shigeru ^a   Kikuchi, Migaku ^a   Hata, Yoshihito ^a   Abe, Shichiro ^a   Taguchi, Isao ^a   Shimamoto, Ken ^b  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Cardiac relaxant; Diastolc dysfunction model; Diltiazem; K201 (JTV519); Norepinephrine

Indexed keywords

4 [3 (4 BENZYL 1 PIPERIDINYL)PROPIONYL] 2,3,4,5 TETRAHYDRO 7 METHOXY 1,4 BENZOTHIAZEPINE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BENZOTHIAZEPINE DERIVATIVE; CALCIUM ION; DILTIAZEM; NORADRENALIN; PROTEIN KINASE C; TROPONIN I;

ADRENERGIC RECEPTOR BLOCKING; ANIMAL TISSUE; AORTA VALVE; ARTICLE; CALCIUM CELL LEVEL; CONTINUOUS INFUSION; CONTROLLED STUDY; DIASTOLE; DIASTOLIC DYSFUNCTION; DIASTOLIC HEART FAILURE; DISEASE SEVERITY; DOSE RESPONSE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HISTOPATHOLOGY; INCIDENCE; LUNG HEMORRHAGE; MALE; MORTALITY; NONHUMAN; PROGNOSIS; RAT; SYSTOLIC HEART FAILURE; TREATMENT OUTCOME;

EID: 33846999283     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20153     Document Type: Article

References (29)

1. Aronow WS. 2001. Left ventricular diastolic heart failure with normal left ventricular systolic function in older persons. J Lab Clin Med 137:316-323.
2. Aurigemma GP, Gaasch WH. 2004. Diastolic heart failure. N Engl J Med 351:1097-1105.
3. Benedict CR, Shelton B, Johnstone DE, Francis G, Greenberg B, Konstam M, Probstfield JL, Yusuf S. 1996. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. Circulation 94:690-697.
4. Bhakta S, Dunlap ME. 2005. Treatment of heart failure with a normal ejection fraction. Curr Treat Options Cardiovasc Med 7:317-325.
5. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. 1984. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311:819-823.
6. Davidson CJ, Bonow RO. 2005. Ventricular pressure in cardiac catheterization. In: Zipes DP, Libby P, Braunwald E. editors. Braunwald's heart disease. A textbook of cardiovascular medicine, 7th edition. Philadelphia: Elsevier. 409p.
7. Eberli FR, Strömer H, Ferrell MA, Varma N, Morgan JP, Neubauer S, Apstein CS. 2000. Lack of direct role for calcium in ischemic diastolic dysfunction in isolated hearts. Circulation 102:2643-2649.
8. Farr MA, Basson CT. 2004. Sparking the failing heart. N Engl J Med 351:185-187.
9. Fleckenstein A. 1983 History of calcium antagonist. Circ Res 52(Suppl I):3-16.
10. Gaasch WH, Zile MR. 2004. Left ventricular diastolic dysfunction and diastolic heart failure. Annu Rev Med 55:373-394.
11. Heywood JT. 1995. Calcium channel blockers for heart rate control in atrial fibrillation complicated by congestive heart failure. Can J Cardiol 11:823-826.
12. Inagaki K, Kihara Y, Hayashida W, Izumi T, Iwanaga Y, Yoneda T, Takeuchi Y, Suyama K, Muso E, Sasayama S. 2000. Anti-ischemic effect of a novel cardioprotective agent, JTV519, is mediated through specific activation of δ-isoform of protein kinase C in rat ventricular myocardium. Circulation 101:797-804.
13. Ito K, Shigematsu S, Sato T, Abe T, Li Y, Arita M. 2000. JTV-519, a novel cardioprotective agent, improves the contractile recovery after ischaemia-reperfusion in coronary perfused guinea-pig ventricular muscles. Br. J Pharmacol 130:767-776.
14. Kaneko N. 1994. New 1,4-benzothiazepine derivative, K201, demonstrates cardioprotective effects against sudden cardiac cell death. Drug Dev Res 33:429-438.
15. Kaneko N, Teraoka K, Horikawa Y, Uchida T, Matsuda R, Hosoda S. 1991. Induction of kinetic cell death and its underlying mechanisms. Jpn Circ J 55:1118-1123.
16. Kaneko N, Ago H, Matsuda R, Inagaki E, Miyano M. 1997a. Crystal structure of annexin V with its ligand K-201 as a calcium channel activity inhibitor. J Mol Biol 274:16-20.
17. 2+ movement in large unilamellar vesicles by K201, a new 1-4 benzothiazepine derivative. Biochim Biophys Acta 1330;1-7.
18. Kaneko N, Matsuda R, Nakajima T, Shinozaki M, Ohtani N, Oda K, Hasumi H, Shimamoto K. 2006. Norepinephrine-induced diastolic dysfunction with aortic valve opening under calcium-loading in rats. Drug Dev Res 67:511-518.
19. Kawabata H, Ryomoto T, Ishikawa K. 2000. Effect of a novel cardioprotective agent, JTV-519, on metabolism, contraction and relaxation in the ischemia-reperfused rabbit heart. Jpn Circ J 64:772-776.
20. Kimura J, Kawahara M, Sakai E, Yatabe J, Nakanishi H. 1999. Effects of a novel cardioprotective drug, JTV-519, on membrane currents of guinea pig ventricular myocytes. Jpn J Pharmacol 79:275-281.
21. + current in guinea-pig ventricular myocytes. Naunyn Schmiedebergs Arch Pharmacol 361:646-653.
22. Kumagai K, Nakashima H, Gondo N, Saku K. 2003. Antiarrhythmic effects of JTV-519, a novel cardioprotective drug, on atrial fibrillation/flutter in a canine sterile pericarditis model. J Cardiovasc Electrophysiol 14:880-884.
23. Mahon N, McKenna WJ. 1998. Calcium channel blockers in cardaic failure. Prog Cardiovasc Dis 41:191-206.
24. Nakaya H, Furusawa Y, Ogura T, Tamagawa M, Uemura H. 2000. Inhibitory effects of JTV-519, a novel cardioprotective drug, on potassium currents and experimental atrial fibrillation in guinea pig hearts. Br J Pharmacol 131:1363-1372.
25. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. 2006. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355:251-259.
26. Sato M, Nagao T, Yamaguchi I, Nakajima H, Kiyomoto A. 1971. Pharmacological studies on a new 1,5-benzothiazepine derivative (CRD-401). Arzneimittelforschung 21:1338-1343.
27. Teichholz LE, Kreulen T, Herman MV, Gorlin R. 1976. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence or absence of asynergy. Am J Cardiol 37:7-11.
28. Wehrens XH, Marks AR. 2004. Novel therapeutic approaches for heart failure by normalizing calcium cycling. Nat Rev Drug Discov 3:565-573.
29. Wehrens XH, Lehnart SE, Reiken SR, Deng S-X, Vest JA, Cervantes D, Coromilas J, Landry DW Marks AR. 2004. Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2. Science 304:292-296.